Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Leukemia 1Bronchiolitis Obliterans Syndrome 1

Interventions

Azacitidine 33venetoclax 10decitabine and cedazuridine drug combination 7Decitabine 7sabatolimab 3pevonedistat 3cedazuridine 3ON 01910 3spartalizumab 2glasdegib 2cc-486 2Panobinostat 2Cytarabine 2BI 6727 211-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 2zanubrutinib 1triciribine 1tipifarnib 1terameprocol 1tapotoclax 1tagraxofusp 1ruxolitinib 1orludodstat 1navitoclax 1lonafarnib 1lintuzumab 1lenzilumab 1guadecitabine 1exatecan 1bisantrene 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Leukemia, Myelomonocytic, Chronic × Vision, Ocular × Clear all
NCT02085798 2020-01-27

Health Outcomes of Recently Diagnosed Myelodysplastic Syndrome (MDS)/Chronic Myelomonocytic Leukemia (CMML) Patients Depending on Treatment Strategy (Wait and See, Support, Active Treatment)

Celgene

Completed
503 enrolled
MyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡